PremiumRatingsAstraZeneca: Buy Rating Reaffirmed as Robust Pipeline and Strategic Optionality Drive Price Target Raise to $1781d agoAZN
AstraZeneca: Buy Rating Reaffirmed as Robust Pipeline and Strategic Optionality Drive Price Target Raise to $178
PremiumRatingsSachin Jain Reiterates Buy on AstraZeneca with Unchanged 16,500 GBp Price Target Amid Valuation Opportunity and Robust Late-Stage Pipeline1d agoAZN
Sachin Jain Reiterates Buy on AstraZeneca with Unchanged 16,500 GBp Price Target Amid Valuation Opportunity and Robust Late-Stage Pipeline